Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT. Robbins Y, et al. Among authors: clavijo pe. Elife. 2020 Jul 7;9:e54854. doi: 10.7554/eLife.54854. Elife. 2020. PMID: 32633234 Free PMC article.
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C. Friedman J, et al. Among authors: clavijo pe. Clin Cancer Res. 2020 Feb 1;26(3):679-689. doi: 10.1158/1078-0432.CCR-19-2209. Epub 2019 Oct 23. Clin Cancer Res. 2020. PMID: 31645352 Free PMC article.
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C. Greene S, et al. Among authors: clavijo pe. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. doi: 10.1158/1078-0432.CCR-19-2625. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848188 Free PMC article.
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Lee MY, et al. Among authors: clavijo pe. J Immunother Cancer. 2021 Mar;9(3):e002128. doi: 10.1136/jitc-2020-002128. J Immunother Cancer. 2021. PMID: 33741731 Free PMC article.
58 results